EU approves first acute migraine drug, potentially a breakthrough for millions

A groundbreaking new treatment for migraine attacks has received approval from the European Commission, potentially offering relief to millions. Aquipta, containing the active substance atogepant, is the first drug authorized in the European Union for the acute treatment of migraine attacks in adults.

Clinical studies, including the phase III ECLIPSE trial, demonstrated Aquipta's efficacy. The medication effectively reduces migraine pain within two hours of administration, with relief lasting up to 48 hours. Previously, atogepant was available only for preventive treatment of migraines, but this new authorization allows patients to use it on demand when an attack begins.

Migraine, a debilitating neurological condition, affects approximately 14% of the global population, with women being more frequently affected than men. Attacks, common in individuals aged 25 to 55, can cause severe throbbing headaches, cognitive impairment, heightened sensitivity to light and sound, and nausea, significantly disrupting daily life. In Poland alone, an estimated 4 million people suffer from migraines, representing a substantial social and financial burden on patients and healthcare systems.

Aquipta belongs to a novel class of drugs called gepants, which work by blocking the CGRP protein believed to trigger inflammation and migraine pain. This dual capability, preventing migraines and effectively treating acute attacks, marks a significant advancement in managing the condition within the EU.